{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:30:10Z","timestamp":1793262610671,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["Z1A HD009005"],"award-info":[{"award-number":["Z1A HD009005"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["NCT04443907"],"award-info":[{"award-number":["NCT04443907"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jtct.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T21:17:38Z","timestamp":1718227058000},"page":"737-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pediatric Cancer Immunotherapy and Potential for Impact on Fertility: A Need for Evidence-Based Guidance"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5513-1233","authenticated-orcid":false,"given":"John A.","family":"Ligon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7476-739X","authenticated-orcid":false,"given":"Margaret C.","family":"Cupit-Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-1113","authenticated-orcid":false,"given":"Seth","family":"Rotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-2081","authenticated-orcid":false,"given":"Akshay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Gomez-Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.06.006_bib0001","series-title":"Cancer Facts & Figures 2024","year":"2024"},{"issue":"10","key":"10.1016\/j.jtct.2024.06.006_bib0002","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/pon.6212","article-title":"Greater fertility distress and avoidance relate to poorer decision making about family building after cancer among adolescent and young adult female survivors","volume":"32","author":"Benedict","year":"2023","journal-title":"Psychooncology"},{"issue":"1","key":"10.1016\/j.jtct.2024.06.006_bib0003","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MOP.0000000000001091","article-title":"Fertility preservation in children and young adults with cancer","volume":"34","author":"Brungardt","year":"2022","journal-title":"Curr Opin Pediatr"},{"issue":"19","key":"10.1016\/j.jtct.2024.06.006_bib0004","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2024.06.006_bib0005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.fertnstert.2018.05.034","article-title":"Electronic address Aao. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion","volume":"110","year":"2018","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.jtct.2024.06.006_bib0006","doi-asserted-by":"crossref","first-page":"66","DOI":"10.6004\/jnccn.2018.0001","article-title":"Adolescent and young adult oncology, version 2.2018, NCCN clinical practice guidelines in oncology","volume":"16","author":"Coccia","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.jtct.2024.06.006_bib0007","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-3994","article-title":"Fertility preservation for pediatric and adolescent patients with cancer: medical and ethical considerations","volume":"145","author":"Klipstein","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.jtct.2024.06.006_bib0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/ejh.14100","article-title":"Long-term survivorship care after CAR-T cell therapy","volume":"112","author":"Puckrin","year":"2024","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2024.06.006_bib0009","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.hoc.2023.05.010","article-title":"Early and late toxicities of chimeric antigen receptor T-cells","volume":"37","author":"Epperly","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jtct.2024.06.006_bib0010","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s11912-023-01401-9","article-title":"Current issues in fertility preservation among pediatric and adolescent cancer patients","volume":"25","author":"Nelson","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.jtct.2024.06.006_bib0011","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1634\/theoncologist.2019-0837","article-title":"It is time to talk about fertility and immunotherapy","volume":"25","author":"Duma","year":"2020","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.jtct.2024.06.006_bib0012","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMra1614676","article-title":"Fertility preservation in women","volume":"377","author":"Donnez","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.06.006_bib0013","series-title":"Speroff's Clinical Gynecologic Endocrinology and Infertility","author":"Taylor","year":"2020"},{"issue":"10","key":"10.1016\/j.jtct.2024.06.006_bib0014","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1093\/oxfordjournals.humrep.a137570","article-title":"Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause","volume":"7","author":"Faddy","year":"1992","journal-title":"Hum Reprod"},{"key":"10.1016\/j.jtct.2024.06.006_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.574263","article-title":"The clinical value and interpretation of anti-mullerian hormone in women with cancer","volume":"11","author":"Anderson","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.jtct.2024.06.006_bib0016","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.fertnstert.2012.09.039","article-title":"Pretreatment antim\u00fcllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy","volume":"99","author":"Dillon","year":"2013","journal-title":"Fertil Steril"},{"issue":"11","key":"10.1016\/j.jtct.2024.06.006_bib0017","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.18.00965","article-title":"Gonadal functioning and perceptions of infertility risk among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study","volume":"37","author":"Lehmann","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.06.006_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.877537","article-title":"Fertility preservation and restoration options for pre-pubertal male cancer patients: current approaches","volume":"13","author":"Eugeni","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.jtct.2024.06.006_bib0019","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1089\/jayao.2020.0012","article-title":"Standardizing risk assessment for treatment-related gonadal insufficiency and infertility in childhood adolescent and young adult cancer: the pediatric initiative network risk stratification system","volume":"9","author":"Meacham","year":"2020","journal-title":"J Adolesc Young Adult Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2024.06.006_bib0020","doi-asserted-by":"crossref","first-page":"e30407","DOI":"10.1002\/pbc.30407","article-title":"Fertility preservation in pediatric leukemia and lymphoma: a report from the children's oncology group","volume":"70","author":"Close","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.jtct.2024.06.006_bib0021","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.fertnstert.2020.09.134","article-title":"Electronic address AAO, Practice Committee of the American Society for Reproductive M. Testing and interpreting measures of ovarian reserve: a committee opinion","volume":"114","year":"2020","journal-title":"Fertil Steril"},{"issue":"5","key":"10.1016\/j.jtct.2024.06.006_bib0022","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/andr.13033","article-title":"Postpubertal spermatogonial stem cell transplantation restores functional sperm production in rhesus monkeys irradiated before and after puberty","volume":"9","author":"Shetty","year":"2021","journal-title":"Andrology"},{"issue":"5","key":"10.1016\/j.jtct.2024.06.006_bib0023","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/andr.12807","article-title":"Restoration of functional sperm production in irradiated pubertal rhesus monkeys by spermatogonial stem cell transplantation","volume":"8","author":"Shetty","year":"2020","journal-title":"Andrology"},{"issue":"6","key":"10.1016\/j.jtct.2024.06.006_bib0024","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/humrep\/dez043","article-title":"Testicular tissue cryopreservation: 8 years of experience from a coordinated network of academic centers","volume":"34","author":"Valli-Pulaski","year":"2019","journal-title":"Hum Reprod"},{"issue":"4","key":"10.1016\/j.jtct.2024.06.006_bib0025","first-page":"203","article-title":"A study of leukemic cell infiltration in the testis and ovary","volume":"23","author":"Kamiyama","year":"1976","journal-title":"Bull Tokyo Med Dent Univ"},{"issue":"3","key":"10.1016\/j.jtct.2024.06.006_bib0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi","year":"2020","journal-title":"Antibodies (Basel)"},{"issue":"7897","key":"10.1016\/j.jtct.2024.06.006_bib0027","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jtct.2024.06.006_bib0028","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jcyt.2022.10.002","article-title":"Emerging frontiers in immuno- and gene therapy for cancer","volume":"25","author":"Gustafson","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2024.06.006_bib0057","unstructured":"United Therapeutics Corp. Unituxin (dinutuximab) [package insert]. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125516s000lbl.pdf. Revised March 2015. Accessed April 3, 2024."},{"issue":"3","key":"10.1016\/j.jtct.2024.06.006_bib0058","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40263-015-0238-y","article-title":"Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs","volume":"29","author":"Amato","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jtct.2024.06.006_bib0059","unstructured":"Genentech. Actemra (tocilizumab) [package insert]. U.S. Food and Drug Administration website:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125276s092lbl.pdf. Revised October 2013. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0060","unstructured":"Genentech. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5250lbl.pdf. Revised October 2010. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0061","unstructured":"Genentech. Avastin (bevacizumab) [package insert]. U.S. Food and Drug Administration website: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125085s340lbl.pdf. Revised September 2022. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0062","unstructured":"GlaxoSmithKline. Ojjaara (momelotinib) [package insert]. U.S. Food and Drug Administration website: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216873s000lbl.pdf. Revised September 2023. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0063","unstructured":"Eli Lilly and Company. Erbitux (cetuximab) [package insert]. U.S. Food and Drug Administration website: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125084s273lbl.pdf. Revised April 2019. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0064","unstructured":"Genentech. Polivy (polatuzumab) [package insert]. U.S. Food and Drug Administration website:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf. Revised June 2019. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0065","unstructured":"Amgen. Blincyto (blinatumomab) [package insert]. U.S. Food and Drug Administration website:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125557lbl.pdf. Revised December 2014. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0066","unstructured":"Amgen. Aimovig (erenumab-aooe) [package insert]. U.S. Food and Drug Administration website:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761077s009lbl.pdf. Revised February 2021. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0067","unstructured":"Seattle Genetics, Inc. Adcetris (brentuximab vedotin [package insert]. U.S. Food and Drug Administration website:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125388_s056s078lbl.pdf. Revised November 2014. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0068","unstructured":"Pfizer Inc. Mylotarg (gemtuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761060lbl.pdf. Revised September 2017. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0069","unstructured":"Pfizer Inc. Besponsa (inotuzumab ozogamicin) [package insert]. U.S. Food and Drug Administration website:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761040s000lbl.pdf. Revised August 2017. Accessed April 3, 2024."},{"issue":"8","key":"10.1016\/j.jtct.2024.06.006_bib0070","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s10815-022-02548-3","article-title":"Primary ovarian insufficiency secondary to chemotherapy with inotuzumab ozogamicin and other agents","volume":"39","author":"Maristany","year":"2022","journal-title":"J Assist Reprod Genet"},{"issue":"8","key":"10.1016\/j.jtct.2024.06.006_bib0046","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaoncol.2020.1641","article-title":"Association of impaired spermatogenesis with the use of immune checkpoint inhibitors in patients with metastatic melanoma","volume":"6","author":"Scovell","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2024.06.006_bib0047","article-title":"Onset of azoospermia in man treated with ipilimumab\/nivolumab for BRAF negative metastatic melanoma","volume":"34","author":"Rabinowitz","year":"2021","journal-title":"Urol Case Rep"},{"key":"10.1016\/j.jtct.2024.06.006_bib0071","unstructured":"AstraZeneca. Imfinzi (durvalumab) [package insert]. U.S. Food and Drug Administration website: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761069s033lbl.pdf. Revised November 2022. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0072","unstructured":"Genentech. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761034s042lbl.pdf. Revised October 2021. Accessed April 3, 2024."},{"key":"10.1016\/j.jtct.2024.06.006_bib0073","unstructured":"EMD Serono. Bavencio (avelumab) [package insert]. U.S. Food and Drug Administration website:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761049s009lbl.pdf. Revised June 2020. Accessed April 3, 2024."},{"issue":"4","key":"10.1016\/j.jtct.2024.06.006_bib0029","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.jtct.2024.06.006_bib0030","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jtct.2024.06.006_bib0031","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jtct.2024.06.006_bib0032","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2024.06.006_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","article-title":"Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice","volume":"3","author":"Winship","year":"2022","journal-title":"Nat Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2024.06.006_bib0034","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/oxfordjournals.humrep.a019256","article-title":"Localization and characterization of white blood cell populations within the human ovary throughout the menstrual cycle and menopause","volume":"11","author":"Best","year":"1996","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.jtct.2024.06.006_bib0035","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/humupd\/dmh011","article-title":"Macrophage contributions to ovarian function","volume":"10","author":"Wu","year":"2004","journal-title":"Hum Reprod Update"},{"issue":"2","key":"10.1016\/j.jtct.2024.06.006_bib0036","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1439-0272.1993.tb02688.x","article-title":"Antigen non-specific tissue damage in T cell-mediated experimental autoimmune orchitis: preliminary characterization of a testis-specific T-cell line by using dermal tissue and cells","volume":"25","author":"Itoh","year":"1993","journal-title":"Andrologia"},{"issue":"10","key":"10.1016\/j.jtct.2024.06.006_bib0037","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s00262-021-02882-y","article-title":"Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma","volume":"70","author":"Tulchiner","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10.1016\/j.jtct.2024.06.006_bib0038","doi-asserted-by":"crossref","DOI":"10.1530\/EC-22-0513","article-title":"Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer","volume":"12","author":"Percik","year":"2023","journal-title":"Endocr Connect"},{"issue":"3","key":"10.1016\/j.jtct.2024.06.006_bib0039","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","article-title":"Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase","volume":"69","author":"Bai","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.jtct.2024.06.006_bib0040","unstructured":"Genentech. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761034s028lbl.pdf. Revised July 2020. Accessed June 26, 2024."},{"issue":"1","key":"10.1016\/j.jtct.2024.06.006_bib0041","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-21-0209","article-title":"Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse","volume":"252","author":"Xu","year":"2021","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.jtct.2024.06.006_bib0042","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-21-0209","article-title":"Effects of PD-1 blockade on ovarian follicles in a prepubertal female mouse","volume":"252","author":"Xu","year":"2022","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.jtct.2024.06.006_bib0043","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.rbmo.2021.09.004","article-title":"Targeted cancer treatment and fertility: effect of immunotherapy and small molecule inhibitors on female reproduction","volume":"44","author":"Bussies","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.jtct.2024.06.006_bib0044","series-title":"Oncofertility Consortium Conference","first-page":"6","article-title":"Elucidating the effects of CAR-T cell therapy on ovarian follicle development in an AML tumor mouse model","author":"Kavarthapu","year":"2023"},{"issue":"4","key":"10.1016\/j.jtct.2024.06.006_bib0045","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11764-014-0369-z","article-title":"Factors associated with pregnancy attempts among female young adult cancer survivors","volume":"8","author":"Dominick","year":"2014","journal-title":"J Cancer Surviv"},{"issue":"9","key":"10.1016\/j.jtct.2024.06.006_bib0048","doi-asserted-by":"crossref","first-page":"605.e1","DOI":"10.1016\/j.jtct.2022.06.002","article-title":"Fertility and CAR T-cells: current practice and future directions","volume":"28","author":"Ligon","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2024.06.006_bib0049","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.3390\/cancers13122881","article-title":"Male and female fertility: prevention and monitoring Hodgkin\u2019 lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi","volume":"13","author":"Viviani","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.jtct.2024.06.006_bib0050","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1200\/JCO.2006.06.5888","article-title":"American Society of Clinical Oncology recommendations on fertility preservation in cancer patients","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.06.006_bib0051","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1148314","article-title":"National oncofertility registries around the globe: a pilot survey","volume":"14","author":"Ozimek","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.jtct.2024.06.006_bib0052","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10815-020-01983-4","article-title":"A view from the past into our collective future: the oncofertility consortium vision statement","volume":"38","author":"Woodruff","year":"2021","journal-title":"J Assist Reprod Genet"},{"issue":"5","key":"10.1016\/j.jtct.2024.06.006_bib0053","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jadohealth.2018.10.297","article-title":"Development of a pediatric fertility preservation program: a report from the pediatric initiative network of the oncofertility consortium","volume":"64","author":"Moravek","year":"2019","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.jtct.2024.06.006_bib0054","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/GO.22.00007","article-title":"Creating a global community of practice for oncofertility","volume":"6","author":"Ataman","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.jtct.2024.06.006_bib0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-0-387-72293-1_17","article-title":"Oncofertility consortium consensus statement: guidelines for ovarian tissue cryopreservation","volume":"138","author":"Backhus","year":"2007","journal-title":"Cancer Treat Res"},{"issue":"9","key":"10.1016\/j.jtct.2024.06.006_bib0056","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724004639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724004639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:00:23Z","timestamp":1778922023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724004639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2666636724004639"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.06.006","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric Cancer Immunotherapy and Potential for Impact on Fertility: A Need for Evidence-Based Guidance","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}